drugset / Trial / NCT05481411
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
Timeline
- Start
- 2022-09-13
- Primary completion
- 2023-04-05
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olpasiran | Unknown | — | Subcutaneous |
Indications
No indication recorded.